Search results
- (-) Remove Press releases filter Press releases
Oxford BioMedica Announces Presentation Of New Clinical Data From ProSavin® Phase I/II Study in Parkinson’s Disease
-- Six-month data from third cohort presented at ASGCT 14th Annual Meeting --
Oxford BioMedica Interim Management Statement May 2011
Oxford, UK – 18 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, t
Oxford BioMedica Broadens 5T4 Antibody Collaboration With Pfizer
-- Diagnostic rights secured for Investigational New Drug application --
Oxford BioMedica Board Changes
Oxford, UK – 21 March 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company,
Oxford BioMedica Announces US IND Approval for Novel Ocular Product in Stargardt Disease
-- Second of four products in Phase I/II ocular programme partnered with sanofi-aventis approved to enter clinical development --
Oxford BioMedica Appoints James Christie as New Head of Manufacturing
Oxford, UK – 9 February 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy compan
Oxford BioMedica Acquires GMP Manufacturing Facility
-- Support for Oxford BioMedica’s five LentiVector® technology-based programmes --